MedTrace Logo

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

NCT05007769 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-11-05

No results posted yet for this study

Summary

The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of the combination, the investigators propose a comprehensive analysis of paired peripheral blood samples collected during this study.

Conditions

Interventions

DRUG

Ramucirumab

Will be supplied by Lilly Oncology, free of charge to the participant

DRUG

Atezolizumab

Atezolizumab will be commercially available.

DRUG

N-803

Will be supplied free of charge to the participants by ImmunityBio

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • ImmunityBio, Inc.

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Daniel Morgensztern, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2024-04-30
Completion
2026-04-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007769 on ClinicalTrials.gov